Thank afternoon, appreciate today. us joining everyone. you, good you We and Jennifer
The record-quarterly one pipeline and with for achieving second milestones. programs sales important number a of our once again was quarter another OMIDRIA strong generating Omeros
today update Let's begin or microangiopathy our stem inhibitor MASP-X cell thrombotic toward and narsoplimab our with regulatory our progress transplant-associated in TMA. approvals stem cell
awaiting BLA are proposed rolling submission for and schedule agency's of we our License U.S., FDA the Biologics Application to In or submitted have response. our the
cell function. set both our as clinical of first and Given primary for The by in deceased quarter. we organ markers targeting stem mid response-based of the are submission of usual timing module laboratory TMA our and BLAs the measures of indicators process, is scheduling endpoint process includes patients data next
that endpoint, competitive that FDA that and are that not is we stem endpoint agreed such there approved endpoint given the specific say them. based. yet of we cell not fair meet drug TMA is to they be data on an approval the would which this the It's criteria for For no confident not released on our details to though first reasons, and would could approval which have have grant
the are module. additional be adverse to of no are remaining The No each clinical written narsoplimab response and collection and narratives and to data majority in-house, good in BLA's already data of to required patient's narsoplimab the trial decease look of already is enrolled. the clinical signals. safety inclusion profile being have A patients continues there for underway are been safety describing course
progress Now on let's Chemistry at CMC. Controls our and Manufacturing or look
are well-positioned. Here again, we
In FDA. completed addition for and we to agency locking BLA. approval can are our down approval, CMC have we for discussed the FDA meet them. requirements The meeting pre-BLA successful the with data CMC to clinical our we of confident and Again, the reviewed that non-clinical requirements date with a we
Lonza, clinical now our for long-term long-standing operating drug. development of narsoplimab is commercial manufacturing partner during the the a of agreement under
filling which established have packaging provide their for commercial they in Vetter, also services will with and aseptic world-leader a We agreement under narsoplimab. a long-term
of meetings approval begun Authorization and assist process. the and will rapporteurs with have we throughout our preparations expected the the through Europe, In submission who or MAA us Application Marketing
the in to data approval same manufacturing and for clinical use is plan non-clinical Europe. Our
cell and reviewed and and MAA FDA designations from as the in narsoplimab time savings each BLA designation U.S. for both exclusivity market any therapy approval. breakthrough TMA and the well With fees, as stem Europe, orphan drug enjoy following in and
continues with and Our the for narsoplimab is engage centers commercial and U.S. thought to leaders transplant and the preparing team in launch Europe. actively
innovation not providing is this The patients leading a this Omeros standard is targeted guidance as complement favorable narsoplimab and MASP-X we the adequately Omeros for patients. creates need way. of a an profile. options its safety cell efficacy space are of programs, treating excited These are community a for MASP-X and greater as stem that and care are the There can opportunity transplant TMA members in the how a welcome with complement on to leader current pathway inhibitor establish and in lectin-specific promises space for with therapeutic
TMA, overall continue gained discussions market organ in to access ways outpatient to treating used formulate of also that therapy. both providers life-saving dialysis and with sites approach the hospitalizations, narsoplimab space, payers care and notably hospital on flexibility extended appropriately focus acute stem cost inpatient We as settings, intensive allowing on These position across to care narsoplimab feedback over expected of and the the reduce expected Narsoplimab most our be is the cell commercial payer a failure. to from also have insightful to how the unit associated therapeutic. is dose course
community narsoplimab for establish value and we of is to-date, of will care and us with and feedback that The for are payers proposition on narsoplimab discussions cell healthcare as stem this other members TMA to and work strong based providers, indication. standard the encouraged
continues Asia. Progress sites the advancing as program in Enrollment numerous IgA and is well. U.S., narsoplimab the nephropathy X Phase in at for Europe and
result likely proteinuria receive the data proteinuria approval based is Filtration development other the approval a patients process. nephropathy to grams. approval ability in gram Either alone. the years than or levels Glomerular approval of IgA based these proteinuria save narsoplimab reduction require with All full greater drugs of in approval. proteinuria GFR reminder, two obtain only is two greater knowledge, full drug or for that The on alone. To to Rate for X a accelerated well on subset full three patients as proteinuria enrolling on in narsoplimab full populations of would As can with our of than discreet as can daily trial XX-hour X full
It submitted Phase the from describes FDA's to nephropathy academic Agency X is the also response few and reviewed drug also the also next our from Glomerular is narsoplimab peer for FDA Vasculitis-associated breakthrough progressive will quickly program has for this nephropathy. treatment within deteriorating publication manuscript by has therapy by committee Medicine's An has impressive Narsoplimab A be prepared rapidly only the orphan detailing clinical IgA our IgA for data leadership designations indication. drug both European with to for designation patient due case Nephritis. the who a interesting weeks. and publication. IgA nephritis report been prepared and been It
also case details soon. to report We the of expect this be published
with In potential expected Enrollment together pharmacodynamics in will or a study, to disease. IgA and is evaluated begin this nephropathy next. this biomarkers narsoplimab pharmacokinetics subcutaneously be separate have with patients administered month of
DMA narsoplimab X AHUS. Atypical is sites Subcutaneous dosing study is continues also enroll of the in trial patients initial of track hemolytic and at orphan trial in drug for guidance planned AHUS. XX and in open accelerated multiple This enrollment support with approval U.S. full administration from the single in arm in for Europe. to Narsoplimab our FDA syndrome Phase approval FDA designations based and or a a on has fast internationally. patients route This of to label both uremic
cycle life are MASP-X nicely. advancing products also Our
MASP-X small for Our of a once clinical in is is MASP-X second of also entry better. orderly is targeting and mid-XXXX subcutaneous available monthly progressing. Development our molecules planned generation antibody or dosing frequency
clinical drug structure-based trials. optimize to X-ray design a for compounds by continue preparation in these Assisted crystallography, we using
compound of to With achieve goal pathway. multiple expect that selective oblates potent by series clinic inhibitors, of highly lectin mid-XXXX, to effectively we the advancing orally our and a the MASP-X available once-a-day
overview and to performance only product the an to turn Now product. OMIDRIA, our of prevent the for in the commercial FDA-approved of numbers reduced cataract quarter pupil constriction pain. for use and the surgery let's post-operative
came their an norms. increase historical $XX.X growth million, delivered for with net OMIDRIA quarter of of another record the at over sales second the The other accounts both remained customers. penetration Days veteran's first at sales administration channels. quarter. inventory and XX% The the increased government in number within in hospitals, demand and across increase accounts driven ASCs, all from by substantial of
share. was loss $X.X net or million includes for million $X.XX which non-cash of Our share the or per quarter $X.XX per $XX.X charges
As we for subsequently no $XX.X may property line of covenants under we not we $XX credit collateral. on pledge facility of Silicon contains had Valley our receivable million our borrowing as our accounts borrow entered general outstanding into up availability of required Bank, June depending and balance. with of which with primarily financial intellectual line any The XXXX to operations. credit We million to revolving XX, available were
line current of With have expenses, over capital. one and credit revolving operating year we revenues the of at
we growth of projected, As continued double with demand in and and growth are the expect sales digit previous in OMIDRIA QX. Consistent quarter expanding coverage second key again increasing was strong physician drivers. payer growth, sales
Let's first made payer on the progress examine front. our
ensure continue teams meet reimbursement OMIDRIA. to field to Our appropriate coverage payers with for and
to Additionally, surgeons payer we with and for payment advocate partnering their all are administrators plans. across separate
for standardize and insurance Advantage, drugs and codes facilitating plans, streamlining Code by permanent July, for OMIDRIA. a Medicaid the J other government OMIDRIA submission and J of issued payers by a in Codes In are Codes used claims, that insurance reimbursement. J Medicare payment physician. Medicare, commercial administered CMS like billing are reimbursement unique
We many drug's and J permanent commercial providers do to under that C Medicare Advantage currently the not the current newly-assigned insurers OMIDRIA reimbursing reimburse begin Code. for under expect Code
than now effective be only in permanent January to OMIDRIA quarterly are made on X, J Previously awards will annually, for less on implementing two we pleased is learn effective Code CMS the X. October months, and that
us that started Code informed new commercialization payer day already facilities sales to effective. from J the in set and October ready teams are access have for ensure plan their market go will the and OMIDRIA fully-aware X, J confirmations J plans. up implementation on be for those receiving We that the their use example Humana Our have to ready executing begun and Code to system becomes has Code. is and the
increasingly outcome Physician proven as published compared facility significant demand this administrators. focus other to repeatedly by continues are a quality and of alternative to of and any measures data, grow the and safety as OMIDRIA surgeons benefits become
studies reduces total of Cystoid peer-review evaluating approximately showed submission this the important patients studies results OMIDRIA CME. peer-reviewed a play CME complication from Edema on Macular building X,XXX the an is for incidents or planned detailing independent that Two OMIDRIA are a cataract month. role these sight-threatening in and surgery this the studies to data publications Independent journals support. in two of of
to In OMIDRIA rate did OMIDRIA studies, these of those any a CME. the without as in with three of treated not steroids were receiving reduction twelve-fold receive The patients patients each steroids. had OMIDRIA-treated where
manage which and times a of and problems frequently to assessed to also of steroids. One is occurred extreme OMIDRIA also these pain iris the Each less light. photophobia compared of examined breakthrough and sensitivity about is iritis studies with to inflammation challenge which three the
on allowed the of in postoperative the October. fentanyl receiving were XXx surgical or patients abstract the request results Study likely a American for treatment. This who fentanyl accepted received data In procedure. to of Analog collected. mitigate opioid masked have surgery at Visual ability to were patients were meetings patients to new discomfort also or who less or presentation cataract been now pain scores to were to request during opioids. also pain study of has Ophthalmology OMIDRIA receiving OMIDRIA and the We compares significant and of during than and independent pain study those perioperative have describing OMIDRIA the Academy epinephrin. epinephrin, for Patients need Scale received for patients those VAS
its results opioid data and a management written makes will study A use for and journal. peer-review OMIDRIA submitted opioid pain that internationally-recognized in of by publication resulting developing surgery soon disorder. assessment an of patient reduces The a clear use the the cataract risk disorder be meaningfully expert in
or permanent in continue intend separate these for obtain outpatient rule directly and proposed for to of July. efforts submit off This fourth peer-review published XXXX to pass-through the drug the governs Part in payment payment Medicare which published and B perspective Medicare journals our was patients. previously the studies the was We OMIDRIA comments not to payment which those the not rule system by is surprising helps guide late until to in given slated other just XXXX. as CMS payment is Each to is CMS proposed quarter and OMIDRIA of not also payers. rule from that that come support mentioned
surgery. rule Early review that is analyze the to on policy of separately the advocate proposed our provide behalf non-opioid during indicates continue of and to of its team post-operative that drug. rule relief when CMS intends pain Our for proposed to paying continuing used drugs
indicates addiction. such payment that there warrant pain package CMS XXXX opioid the for drugs show that rule to demonstrated separate a or barrier post-operative that evidence are proposed a to deter for to such payment avoid help of Specifically, non-opioid access drugs. that and reduction if use prescription drugs may in is presents indicated And
of clinical forth that data Phase Based through to fits trials, access separate qualify team by squarely CMS together X clear to recent as on the just pass hiatus, within the data OMIDRIA our with opioid the parameters believes that set for our sparring restriction we well its OMIDRIA discussed payment. as from during
a policy on ensure efforts, Consistent In administration and we ophthalmic addition Cataract system. the for care bad of support Surgery, lower and separate in it that order our surgeons beneficiaries. evidence information meets providing that the clear surgery and package supply Society and for we criteria administrators quality Ophthalmic harms commercial veterans Surgery makes facility OMIDRIA previous Refractive Medicare to Providing into Society have of OMIDRIA received the to characterizing nationwide. CMS American the and that payment, non-opioid of how payment payers with additional as cataract facility the intend to Outpatient is the the than drug a
urge not letters and CMS new do including reimbursement FDA by on existing [indiscernible] mechanisms. its CMS packaged bipartisan These CMS OMIDRIA products ensure that XXXX, the during to to complications for congressional reevaluate Prior ensure policies. the house expect strongly directly bicameral that appropriate and Senate neatly to the is that the drugs will new payment scheduled pass-through save management. pain CMS bipartisan on for like asking of of and and advance patients minimizing continuing ophthalmic pay chairs into will for record we to OMIDRIA CMSs pharmaceutical approved durgery fit request post-operative strong reliance that CMS other and letters Their vision indications and for any referenced like have we addition, in appropriate are reimbursement the for post-operative termination late reducing support CMS drugs beneficiaries Medicare get of who In the reimbursement for thing care payers. separately to we OMIDRIA there. money likely for for do opioids by right standard to
development, the to of from lectin highlights A of our complement results. franchise. of the before pathway or on MASP-X the pro-factor alternative over activator our responsible this Unlike targeting few our on blocking part second without factor complement market today OMSXXX, go began pipeline MASP-X. affecting the D either the is in classical alternative an The on our OMSXXX MASP-X a let's of We the pathways. function inhibitors other conversion part we with of pathway for to programs financial has Now D. some advantage system's selectively pathway, or move comments update is franchise key complement alternative of of the antibody the
We less OMSXXX be expect dosed that subcutaneously, monthly once will or even frequently.
is is about of enter up the half scale to Manufacturing slated this well under way proven and We're excited the of OMSXXX the for molecule. XXXX. first breadth clinic indications
is other and compared Our as the initial market better more is only hemolysis expected extravascular on dosing pathway in nocturnal convenient safety a intravascular not profile, hemoglobinuria, Paroxysmal OMSXXX well. to development to have inhibitors to in disease alternative the inhibit but focus ability hemolysis, which the or
compulsive disorders. Let's addiction and OMSXXX, turn the for PDEX or phosphodiesterase of now treatment X to program our
we over demonstrate our deterrent use. the development. drugs therapies and effective drugs major Here the that multiple of advantages on addiction depress in see depressing inhibitors act marketed treatment a abuse The for again, important and without disorders data system, do the across system. reward addiction reward are the the their market to or PDEX compulsive potential Current of for
has cohorts expect PDEX or inhibitor. Dosing detailed future. the in study being represents clinical and once results food. cohorts dosing this for analysis program Our to from X without release pharmacokinetic focus finalized the in lead Phase is near nicotine large multiple support The our daily both in Data data ascending is we now with need. which unmet a and single and completed trial initial addiction clinical been the
is of manuscript of will a action the PDEX in addition, publication finalized be submitted being inhibition soon detailing for and journal. peer-review mechanism by addiction major In a
in CNS up a is with wrap coupled program. technology development a Omeros GPCRs our that drug program receptor, [ph]. indications cardiovascular We'll XX it ranging believes and summary from our G-protein metabolic This for GPCR to platform controls
primary a receptor [indiscernible] important recently program has our this in been in of GPRXXX, cancer One a with interest immunotherapy. activity
the future. more to program near this expect We in information publicly very about share
turn quarter over Mike With I'll our summary call that, for of second results. financial a the to
